Autopsy report · NCT00125411

Study of Satraplatin (JM-216) in Combination With Docetaxel

“Sponsor decided to discontinue study drug development.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 8 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 28 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Agennix

Sponsor type

Industry

Conditions

Tumors

Interventions

satraplatin and docetaxel

Participants

28

Sites

1

Countries

United States

Trials that died the same way

• Consolidation Therapy in Patients With Metastatic Solid Malignancies
  “Sponsor decision to discontinue study.” (85% match in meaning)
• Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
  “This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.” (84% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (79% match in meaning)
• Serum-Free Thymus Transplantation in DiGeorge Anomaly
  “The sponsor decided to withdraw the study.” (79% match in meaning)
• KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
  “Study discontinued due to sponsor decision.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.